Sparks group health fund steady as committee hears drug-driven cost pressures

The Sparks Group Health Care Committee heard Tuesday that the city’s Group Health Care Fund is in healthy condition but faces growing cost pressure from specialty prescription drugs and newer GLP‑1 therapies.

Wayne Weber, Sparks budget manager, told the committee the fund ended fiscal 2025 with about $11 million and that current reserves equate to roughly 9–10 months of coverage, “which is really good,” while noting there are still three months left in the fiscal year. “So, there was a time when we were negative. Now we’re positive,” Weber said.

LP Insurance and the city’s pharmacy vendor presented the cost drivers behind recent plan trends. Nate Kerr of LP Insurance said employee claims on a per‑employee‑per‑month basis rose about 10% in the January report and that the plan’s incurred‑but‑not‑reported (IBNR) liability stood at roughly $1.25 million through January. “Through the month of January, our claims cost is up about 6½% averaging $1,604 per employee per month,” Kerr said.

Jennifer Salas of Vital One reported the city’s pharmacy plan per member per month was $244.63 for 2025, a 22.9% year‑over‑year trend. She said specialty therapies account for about 64% of overall drug spend while representing a small share of prescriptions; specialty trend rose 39.8% PMPM. Vital One highlighted GLP‑1 class drugs as a growing contributor: in 2025 the GLP‑1 class showed a 24.3% change with 292 claims and 46 utilizers, with Mounjaro and Ozempic named as main cost drivers.

Vital One and LP pointed to several cost‑containment tools already in use and under evaluation: manufacturer‑assistance and managed co‑pay programs, a pharmacist‑led clinical outreach program (Care Improvement Program Plus), a better‑choices formulary layer to steer use away from low‑value high‑cost drugs, and an opioid management program. Salas said those programs have produced savings and may mitigate some specialty spend growth.

Russ Garrett of UMR, the city’s third‑party administrator, provided a claims snapshot for January–February: 7,558 claims processed (5,493 medical, 1,533 pharmacy, 531 dental) with roughly $2.1 million paid year‑to‑date and combined medical+pharmacy PMPM near $739. UMR reported 99.3% in‑network utilization and said it has met accuracy guarantees.

Committee members discussed the balance between preserving a rich benefit for employees and controlling long‑term cost. “Prescription drugs make up a substantial component from a cost perspective of the city’s benefit offering,” Kerr said, noting that any meaningful savings will likely come from plan‑design choices in the prescription benefit and formulary management.

The committee will receive more detailed options at a May 21 workshop; members were asked to collect questions and return them to representatives by April 6. The next steps could include a June special meeting to consider votes on changes for implementation January 1, 2027.

The committee took no binding action on plan design changes at the meeting.